02 November 2015
After successive cancer therapies, multiple subpopulations of cancer cells arise, each with divergent genetic aberrations that may confer drug resistance or susceptibility. Tissue biopsies may not detect these subpopulations, but a liquid biopsy of blood using Epic Sciences' no cell left behind® technology may help identify these important tumor cells and characterize how a patient's tumors have evolved over time.
02 November 2015
ReVision Optics, Inc. (RVO), a leader in implantable presbyopia-correcting corneal inlay technology, announces that clinical data on the company’s Raindrop® Near Vision Inlay was published in the peer-reviewed Journal of Cataract Refractive Surgery. The Raindrop Inlay is a microscopic hydrogel inlay designed to improve near and intermediate vision, thus reducing the need for reading glasses.
China slowdown? Life sciences remains steadfastly immune
02 November 2015
Another year, another Shanghai October packed with conferences. But this time around, the angst of regulatory and reimbursement challenges has been replaced with a growing realization that the momentum of change is accelerating, even if there is considerable unease around how to make the most of it.
Biotech IPOs are staggering as the bulls begin to fade back
02 November 2015
Third Rock startup MyoKardia staggered onto Nasdaq on Wednesday, pricing its IPO at $10 a share--a deep, bargain basement discount from the hefty range it set for itself. The biotech raised $54 million--tens of millions of dollars below its expectations--along with fresh questions over the fate of the biotech IPO window.
Scientists use magnetic nanoparticles to place stem cells to treat TBI
02 November 2015
Using stem cells to treat traumatic brain injury is thought to be promising, but delivering those cells via an injection into the central nervous system is fraught with risk including intracranial hemorrhage and the simple failure of the cells to reach the correct area of the brain.
Why the FDA Is Worried About Chinese Drugs in Your Medicine Cabinet
30 October 2015
When FDA inspectors showed up at a Chinese company that supplies key ingredients to two of the U.S.’s biggest drug companies, a curious thing happened. After lunch, they walked into a quality control lab on the second floor, where they saw a worker pull what looked like a memory stick from a computer and put it in the pocket of his lab coat. The inspectors asked to see what he’d taken.
Top U.S. drugmakers ride new products to strong results
30 October 2015
Growing sales of expensive new cancer drugs and other newer medicines propelled top U.S. drugmakers Pfizer Inc, Merck & Co and Bristol-Myers Squibb Co to stronger-than-expected third-quarter profits. The results, announced on Tuesday, demonstrate that the "patent cliff" that had been hurting earnings as huge-selling drugs like Pfizer's Lipitor and Bristol's Plavix went generic is now well behind these companies.
Drug-device combo from Wyss takes a new approach on treating stroke
30 October 2015
Scientists at the Wyss Institute have led the development of a new drug-device combo aimed at swiftly dissolving blood clots in the brain that cause stroke. The key to the new approach are biodegradable nanoparticles that are coated with a "clot-busting" drug dubbed tissue plasminogen activator, or tPA, which are designed to mimic the activity of blood platelets. They use a stent to open up a narrow opening in a blocked blood vessel.
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results
29 October 2015
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the third quarter ended September 30, 2015.
Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation
29 October 2015
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced today the initiation of the clinical phase of its intravenous (IV) ganaxolone program in Status Epilepticus (SE). Data from preclinical studies yielded positive results testing ganaxolone IV in benzodiazepine-resistant SE, which support progressing ganaxolone IV to human clinical trials. Ganaxolone IV promoted survival and showed better or comparable reversal of seizures than the endogenous neurosteroid, allopregnanolone, in clinically translatable rodent models of SE. The studies were conducted at two separate laboratories using different measurements.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024